XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenetic Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.93−0.06 (-3.02%)
Close on Oct 19, 2026
- Market cap
- $4.43M
- P/E (TTM)
- –
- Dividend yield
- –
Xenetic Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licenses [Member] | – | – | – | – | – | – | – | $0 | $7.50M | – | – | – |
| Collaboration Services [Member] | – | – | – | – | – | – | – | $0 | $85.00K | – | – | – |
| Royalty [Member] | – | – | – | – | $1.16M | $436.94K | $17.07K | $0 | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Xenetic Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.